Global ulcerative colitis industry forecast
According to the ulcerative colitis market analysis, Technavio’s research analysts predict that this market will grow steadily at a CAGR of approximately 7% during the forecast period. The increase in patient assistance programs is a major driver of the market. The provision of these programs by vendors will increase the preference for branded drugs because the out-of-pocket charges would be less as the drugs are obtained at lower costs. The increase in the prevalence of ulcerative colitis is another factor, which is expected to boost ulcerative colitis market growth during the forecast period. According to CDC, the worldwide incidence of ulcerative colitis is between 0.5 to 24.5 cases per 100,000 persons per year. The recurrence of the disease’s symptoms is also high. According to Crohn's and colitis foundation of America, about 30% of the people on remission are expected to suffer from the disease flare-up in the future following the treatment and remission.
Segmentation by molecule type and analysis of the ulcerative colitis market
- Biologics
- Small molecules
In terms of molecule type, the biologics segment dominated the ulcerative colitis market in 2015. The better efficacy and safety of these drugs along with increased uptake, especially in developed markets such as the US and Europe, fuel the growth of this segment.
Geographical segmentation and analysis of the ulcerative colitis market
The Americas accounted for approximately 60% of the market share during 2015 and is expected to grow at a CAGR of around 5% during the forecast period. The increased uptake of biologics, a growing number of ulcerative colitis patients, and the associated health issues are the primary drivers of market growth in this region.
Competitive landscape and key vendors
The global ulcerative colitis market offers a vast opportunity for vendors due to the absence of effective treatment options for ulcerative colitis. As a result, both big and small vendors are shifting their focus and making huge investments in R&D to usher inadequate treatments for ulcerative colitis. Thus, the competition in the market has increased tremendously and to endure this tough competition, vendors need to develop improved and superior techniques to stay on top.
The leading vendors in the market are
- AbbVie
- Janssen Pharmaceutical
- Merck
- Takeda Pharmaceuticals
Other prominent vendors in the market include Abbott, Ajinomoto Pharmaceuticals, Altheus Therapeutics, Amgen, Arena Pharmaceuticals, Astellas Pharma, AstraZeneca, Avaxia Biologics, BioLineRx, Celgene, Cosmo Pharmaceuticals, Eisai, Ferring Pharmaceuticals, Galapagos NV, Genentech, Gilead Sciences, GlaxoSmithKline, Hutchison MediPharma, Immune Pharmaceuticals, InDex Pharmaceuticals, Kaken Pharmaceutical, Kissei Pharmaceutical, Kyowa Hakko Kirin, Lipid Therapeutics, Meda, Mitsubishi Tanabe, Mochida Pharmaceutical, Morphotek, Nestle, Pfizer, Procter & Gamble, Qu Biologics, Receptos, Salix Pharmaceuticals, Santarus, Shield Therapeutics, Shire Pharmaceuticals, Sterna Biologicals, Tillotts Pharma, TopiVert, UCB, and Zeria.
Key questions answered in the report include:
- What will the market size and growth rate be in 2020?
- What are the key factors driving the global ulcerative colitis market?
- What are the key market trends impacting the growth of the global ulcerative colitis market?
- What are the challenges to market growth?
- Who are the key vendors in the global ulcerative colitis market?
- What are the market opportunities and threats faced by the vendors in the global ulcerative colitis market?
- What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
- What are the key outcomes of the five forces analysis of the global ulcerative colitis market?
Technavio also offers customization on reports based on specific client requirement.
Related reports: